BioStock: “Unprecedented” phase II data for Alligator in pancreatic cancer

Alligator Bioscience continues to post convincing phase II data with cancer immunotherapy mitazalimab in pancreatic cancer. Adding to the positive momentum, the Swedish biotech has announced a financing round of up to 80 million MSEK extending its cash runway to Q1 2025. This is setting the company up in a position  of strength for their ongoing partnering discussions. BioStock reached out to Alligator’s CEO Søren Bregenholt for a comment on the company’s hot streak.

Read the article at biostock.se:

https://www.biostock.se/en/2024/07/unprecedented-phase-ii-data-for-alligator-in-pancreatic-cancer/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/